Andrew Patton, MD
Orthopaedic Surgery · Shreveport, LANPI 1649530106
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,200 of the $12,510 with a category attached, or 73.5%. Smith+Nephew accounts for 72.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $5,370 and has fallen 90.4% since, to $513 in 2025.
Across 74 payments — averaging $169.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$9K
- Midsouth Orthopedics Inc.$1K
- Medical Device Business Services, Inc.$1K
- Stryker$598
- Vericel Corporation$249
- Curonix LLC$107
- plus $248 from 7 others
What the payments were for
- Travel & lodging$8637%
- Food & beverage$2,44720%
- Education$9,20074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 36 | $9,092 |
| Midsouth Orthopedics Inc. | 1 | $1,200 |
| Medical Device Business Services, Inc. | 8 | $1,015 |
| Stryker | 12 | $598 |
| Vericel Corporation | 5 | $249 |
| Curonix LLC | 2 | $107 |
| Innovation Technologies Inc | 2 | $63 |
| Vertex | 3 | $48 |
| Medacta USA, Inc. | 1 | $45 |
| Dynasplint Systems Inc. | 1 | $33 |
| Arthrex | 1 | $29 |
| Bioventus LLC | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GRYPHON$835
- MAKO$245
- NA$136
- N/A$136
- INTEllIO LINK WEREWOLF$136
- MACI$123
- AEQUALIS ASCEND FLEX$109
How this compares
$12,510 in reported general payments places this provider in the 75th percentile of 286 orthopaedic surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 110 | $892 |
| Ondansetron Hcl | 65 | $351 |
| Methocarbamol | 46 | $337 |
| Methylprednisolone | 51 | $315 |
| Tramadol Hcl | 83 | $241 |
| Meloxicam | 102 | $180 |
| Gabapentin | 16 | $165 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $135 |
| Cyclobenzaprine Hcl | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Shreveport
- Pierce NunleyShreveport$1.8M
- Steven AtchisonShreveport$170K
- Timothy TalbertShreveport$68K
- Mark CallananShreveport$39K
- Michael NammourShreveport$38K
- Eubulus KerrShreveport$33K
- Massimo MorandiShreveport$28K
- John GoogeShreveport$20K
- Christopher CaldwellShreveport$17K
- Christopher HarrodBaton Rouge$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.